News
12 January
2021

PB012 PureApta on the NCBR beneficiaries’ list of successes

PB012 PureApta was successfully completed. A platform for the selection of modified aptamers for diagnostic and therapeutic use was created, which is the basis for the development of our other projects as well as for commercial activities

The National Center for Research and Development placed the project on the list of beneficiaries’ successes!

Making science happen and being able to put the results of research into practice is a really interesting challenge.

Link: 🔗 PureApta – Successes of beneficiaries

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers